CopAur Minerals Inc. (TSXV:CPAU)

Ligand Pharmaceuticals Balance Sheet

Financials in millions CAD. Fiscal year is July - June.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020
Cash & Equivalents	0.19	0	1.88	1.67	3.27	0
Short-Term Investments	0.38	2.37	-	-	-	-
Cash & Short-Term Investments	0.57	2.37	1.88	1.67	3.27	0
Cash Growth	2236.92%	26.62%	12.00%	-48.83%	73767.33%	-74.81%
Other Receivables	0.06	0.04	0.03	0.19	0.09	0
Receivables	0.06	0.04	0.03	0.19	0.09	0
Prepaid Expenses	0.14	0.1	0.19	0.23	0.45	0.01
Other Current Assets	0.05	0.05	0.05	0.05	0.05	0.05
Total Current Assets	0.82	2.56	2.14	2.14	3.85	0.06
Property, Plant & Equipment	37.91	37.02	38.3	35.62	1.91	0.44
Long-Term Investments	-	-	-	-	-	0.1
Total Assets	38.74	39.58	40.44	37.76	5.77	0.61
Accounts Payable	0.1	0.43	0.55	0.84	0.67	0.04
Accrued Expenses	0.03	0.03	0.07	0.01	0.06	0.11
Current Income Taxes Payable	-	-	0.09	0.09	0.08	0.08
Total Current Liabilities	0.13	0.46	0.71	0.94	0.81	0.23
Total Liabilities	0.13	0.46	0.71	0.94	0.81	0.23
Common Stock	55.11	52.95	52.46	48.42	24.51	19.45
Retained Earnings	-27.26	-29.05	-27.68	-25.06	-23.72	-22.37
Comprehensive Income & Other	10.76	10.63	10.36	8.89	4.17	3.3
Total Common Equity	38.61	34.52	35.13	32.24	4.96	0.38
Minority Interest	-	4.6	4.6	4.58	-	-
Shareholders' Equity	38.61	39.12	39.73	36.82	4.96	0.38
Total Liabilities & Equity	38.74	39.58	40.44	37.76	5.77	0.61
Net Cash (Debt)	0.57	2.37	1.88	1.67	3.27	0
Net Cash Growth	2236.92%	26.62%	12.00%	-48.83%	73767.33%	-74.81%
Net Cash Per Share	0.01	0.04	0.03	0.06	0.26	0.00
Filing Date Shares Outstanding	81.79	61.96	60.72	50.97	21.53	11
Total Common Shares Outstanding	81.79	60.75	59.72	50.91	21.05	5.08
Working Capital	0.69	2.1	1.43	1.2	3.05	-0.16
Book Value Per Share	0.47	0.57	0.59	0.63	0.24	0.07
Tangible Book Value	38.61	34.52	35.13	32.24	4.96	0.38
Tangible Book Value Per Share	0.47	0.57	0.59	0.63	0.24	0.07

Source: S&P Global Market Intelligence. Standard template. Financial Sources.